Abstract
Inhibition of Chk1 kinase has garnered attention as a possible complement to DNA-damaging chemotherapeutic agents, widening their therapeutic window. As a result, several distinct classes of Chk1 inhibitors have been recently identified with selected compound advancing to clinical trials stage. This review focuses on the challenges and recent progress achieved in this area from a medicinal chemistry perspective.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call